Dose-adjusted EPOCH chemotherapy with bortezomib and raltegravir for human T-cell leukemia virus-associated adult T-cell leukemia lymphoma Journal Article
| Authors: | Ratner, L.; Rauch, D.; Abel, H.; Caruso, B.; Noy, A.; Barta, S. K.; Parekh, S.; Ramos, J. C.; Ambinder, R.; Phillips, A.; Harding, J.; Baydoun, H. H.; Cheng, X.; Jacobson, S. |
| Article Title: | Dose-adjusted EPOCH chemotherapy with bortezomib and raltegravir for human T-cell leukemia virus-associated adult T-cell leukemia lymphoma |
| Keywords: | treatment outcome; genetics; prednisone; mortality; doxorubicin; antineoplastic agent; bortezomib; etoposide; antineoplastic combined chemotherapy protocols; cyclophosphamide; vincristine; virology; htlv-i infections; human t-lymphotropic virus 1; leukemia-lymphoma, adult t-cell; complication; humans; human; raltegravir; htlv-1 infection; raltegravir potassium |
| Journal Title: | Blood Cancer Journal |
| Volume: | 6 |
| ISSN: | 2044-5385 |
| Publisher: | Nature Publishing Group |
| Date Published: | 2016-03-25 |
| Start Page: | e408 |
| Language: | English |
| DOI: | 10.1038/bcj.2016.21 |
| PUBMED: | 27015285 |
| PROVIDER: | scopus |
| PMCID: | PMC4817103 |
| DOI/URL: | |
| Notes: | Letter -- Export Date: 3 April 2017 -- Source: Scopus |
